Amneal is buying Kashiv BioSciences for up to $1.1 billion to become a global leader in affordable biosimilar drugs. Strong Q1 results beat expectations and 2026 guidance raised.
UBS starts coverage on Amneal Pharmaceuticals with a Buy rating. Strong specialty growth, Parkinson’s drugs, and attractive entry point after recent selloff.
Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment.
The FDA has approved Amneal Pharmaceuticals’ new single- and multi-dose epinephrine vials, expanding access to a critical emergency medicine used for allergic reactions and septic shock in hospitals and acute care settings.
Amneal Pharmaceuticals has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension.
Amneal Pharmaceuticals receives FDA approval for its generic sodium oxybate, offering a more accessible and cost-effective treatment for narcolepsy's excessive sleepiness and cataplexy in patients 7+.
